Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study.
about
Development of oral agent in the treatment of multiple sclerosis: how the first available oral therapy, Fingolimod will change therapeutic paradigm approachDimethyl fumarate for multiple sclerosisDimethyl fumarate for multiple sclerosisDimethyl fumarate in multiple sclerosis: latest developments, evidence and place in therapyDimethyl fumarate in the management of multiple sclerosis: appropriate patient selection and special considerationsOptimizing therapeutics in the management of patients with multiple sclerosis: a review of drug efficacy, dosing, and mechanisms of actionAnti-inflammatory dimethylfumarate: a potential new therapy for asthma?Regression to the mean and predictors of MRI disease activity in RRMS placebo cohorts--is there a place for baseline-to-treatment studies in MS?Design of oral agents for the management of multiple sclerosis: benefit and risk assessment for dimethyl fumarateMultiple sclerosis--new treatment modalitiesUtilization of Dimethyl Fumarate and Related Molecules for Treatment of Multiple Sclerosis, Cancer, and Other DiseasesRisk Mitigation Strategies for Adverse Reactions Associated with the Disease-Modifying Drugs in Multiple SclerosisCellular stress responses, the hormesis paradigm, and vitagenes: novel targets for therapeutic intervention in neurodegenerative disordersDevelopment of oral immunomodulatory agents in the management of multiple sclerosisChemical proteomic map of dimethyl fumarate-sensitive cysteines in primary human T cellsCurrent and emerging therapies in multiple sclerosis: a systematic reviewThe effectiveness of dimethyl fumarate monotherapy in the treatment of relapsing-remitting multiple sclerosis: a systematic review and meta-analysis.Risks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosisEmerging oral treatments in multiple sclerosis - clinical utility of cladribine tabletsFumarate treatment in progressive forms of multiple sclerosis: first results of a single-center observational studyFumaric Acid and its esters: an emerging treatment for multiple sclerosis.Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway.Effect of BG-12 on contrast-enhanced lesions in patients with relapsing--remitting multiple sclerosis: subgroup analyses from the phase 2b study.Dimethyl fumarate in the treatment of relapsing-remitting multiple sclerosis: an overview.Neuroprotective strategies involving ROS in Alzheimer disease.Oral disease-modifying therapies for multiple sclerosis.Sex hormonal regulation and hormesis in aging and longevity: role of vitagenesEmerging therapies for treatment of multiple sclerosisDimethyl fumarate inhibits dendritic cell maturation via nuclear factor κB (NF-κB) and extracellular signal-regulated kinase 1 and 2 (ERK1/2) and mitogen stress-activated kinase 1 (MSK1) signaling.Vitamin D₃ and monomethyl fumarate enhance natural killer cell lysis of dendritic cells and ameliorate the clinical score in mice suffering from experimental autoimmune encephalomyelitis.Dimethyl fumarate treatment alters circulating T helper cell subsets in multiple sclerosis.Recent advances in treating multiple sclerosis: efficacy, risks and place in therapy.Oral available agents in the treatment of relapsing remitting multiple sclerosis: an overview of merits and culprits.Dimethyl fumarate treatment of relapsing-remitting multiple sclerosis influences B-cell subsets.New and Emerging Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: What is New and What is to Come.Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis.Dimethyl fumarate modulation of immune and antioxidant responses: application to HIV therapy.Multiple sclerosis: Five new things.Fumarates for the treatment of multiple sclerosis: potential mechanisms of action and clinical studies.Update on the treatment options for multiple sclerosis.
P2860
Q22305854-BDCB9731-325C-47E9-A39C-8860E5DF47DAQ24186433-DE771222-76F1-43BE-8196-E6641CE1D155Q24197602-E7D64A38-E30E-4942-A782-0DA03C6DDB4EQ26738969-EE2A4866-4765-46D4-A0B6-761AD560C6D5Q26752859-43242C37-9DD2-47E5-A196-53F803727380Q26822611-FA3613D5-CF67-48C7-9BCA-1FA3B336747AQ26853672-057C518A-8694-452F-A8AF-2737F876D17BQ26998513-95E71B18-5053-4F65-BCE5-71C8271988B2Q27021147-285DDE79-7622-4998-82E1-7A0E46045EE5Q28072906-C5F381B4-D7CB-4C6A-A916-B0189B8E3751Q28078742-38DD4928-02D2-42B7-BD0F-51206AE5CC64Q28087414-C962A8BB-A54E-4E5A-A233-438F738E5245Q28384232-08A8C999-7E79-48E6-8FF2-583100D97B15Q28388704-C5145330-F634-408E-9EC4-9BDB11C55C92Q28821775-F989644B-5A61-4275-82E6-D34C588B87BCQ29010983-DFDF2862-CF5A-43B7-9519-6462CC3CFE03Q33621682-F93D3371-215C-4971-9DAE-9919F8225AC4Q33802186-DF3765FB-6CF2-41FF-8651-D055A9245ACDQ34133316-55B77DFE-B584-4D6F-83D8-F3960ECF7577Q34389325-9B8BB5C3-6765-4090-9493-B0A7986B2C2BQ34611373-0C70C49A-2EDB-4686-B832-2221378F6AF2Q34627230-1B5E6B49-2040-4D07-81BB-3454DE981286Q34631940-65BAEBE8-37BE-481D-B155-24E9630BD694Q34667496-614EEB87-F9B1-4240-A175-039C78C58D1CQ34757939-5FEBB11C-028F-4084-A7AC-F37244D641CAQ34996562-DB8B8C99-C716-4D58-B89A-CE5D9EAA3A49Q35333484-294380F5-91EC-40C9-BC52-F479A8BC62AEQ35557390-95641824-A6E4-4B95-BA92-E47256B3832FQ36201954-4D1AB61B-3C0B-4962-9ED8-FFC48782C720Q36329622-326CA0D3-3131-4D8E-A12A-2DCFD513651AQ36429919-ABD42057-F637-4887-BF97-EE2CA051DF8FQ36515493-4F2720B7-239F-47D2-9B8C-D6966860B136Q36648175-AB247AB3-D6F2-4909-81B1-37AB10EF5FB6Q36669117-B28337C3-EE06-44FA-B06F-E8FE229093BDQ36748702-8B224478-F07E-48D2-9E67-4498BE69B56FQ36975701-54DB55AF-BB0E-4F58-959A-8CF0DB29707FQ37122279-14DF0227-4DD6-4AF7-8274-7EB9F9EF6AC6Q37251695-BF304EA5-1B6A-4EBC-9063-BA23F32C6F7CQ37318146-B797B64D-C30B-43A7-BAEE-B1151A88ADBDQ37729045-CF2D79CC-0347-4D0E-ACDE-BD8AAB8A806B
P2860
Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Oral fumaric acid esters for t ...... seline-controlled pilot study.
@en
Oral fumaric acid esters for t ...... seline-controlled pilot study.
@nl
type
label
Oral fumaric acid esters for t ...... seline-controlled pilot study.
@en
Oral fumaric acid esters for t ...... seline-controlled pilot study.
@nl
prefLabel
Oral fumaric acid esters for t ...... seline-controlled pilot study.
@en
Oral fumaric acid esters for t ...... seline-controlled pilot study.
@nl
P2093
P2860
P1476
Oral fumaric acid esters for t ...... seline-controlled pilot study.
@en
P2093
B Bellenberg
H Przuntek
S Schimrigk
V Hoffmann
P2860
P304
P356
10.1111/J.1468-1331.2006.01292.X
P577
2006-06-01T00:00:00Z